BMS 986094

Drug Profile

BMS 986094

Alternative Names: BMS-986094; HCV NS5b polymerase inhibitors - Inhibitex; HCV polymerase inhibitors - Inhibitex; INX-08189; INX-189

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardiff University; Katholieke Universiteit Leuven; University of Georgia
  • Developer Inhibitex
  • Class Antivirals; Naphthalenes; Nucleosides; Purine nucleotides; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 30 Apr 2013 Duke University initiates a longitudinal study evaluating the incidence of cardiac and renal dysfunction in patients exposed to BMS 986094 in USA (NCT01846494)
  • 23 Aug 2012 Discontinued - Phase-I/II for Hepatitis C in Puerto Rico (PO)
  • 23 Aug 2012 Discontinued - Phase-II for Hepatitis C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top